Article
Ophthalmology
Kentaro Kawai, Manabu Miyata, Sotaro Ooto, Hiroshi Tamura, Naoko Ueda-Arakawa, Ayako Takahashi, Akihito Uji, Yuki Muraoka, Masahiro Miyake, Kenji Yamashiro, Akitaka Tsujikawa
Summary: This study found that a thin subfoveal choroid at baseline and multiple anti-VEGF injections in a PRN regimen increase the risk of developing macular atrophy (MA) involving the fovea after photodynamic therapy (PDT) and PRN treatment.
Article
Multidisciplinary Sciences
Takao Hirano, Yuichi Toriyama, Yoshihiro Takamura, Masahiko Sugimoto, Taiji Nagaoka, Yoshimi Sugiura, Fumiki Okamoto, Michiyuki Saito, Kousuke Noda, Shigeo Yoshida, Akihiro Ishibazawa, Osamu Sawada, Toshinori Murata
Summary: This study demonstrated that a 2-year treat-and-extend aflibercept regimen, combined with adjunct focal/grid laser, could effectively improve BCVA and CST in patients with diabetic macula edema.
SCIENTIFIC REPORTS
(2021)
Article
Multidisciplinary Sciences
Jakkrit Juhong, Pear Ferreira Pongsachareonnont, Thanapong Somkijrungroj, Apivat Mavichak, Adisai Varadisai, Pajaree Chariyavilaskul, Tanittha Chatsuwan, Thitima Benjachat Suttichet, Kittisak Kulvichit
Summary: This study evaluated the sterility, stability, and efficacy of repackaged ziv-aflibercept stored in plastic tuberculin syringes for up to 90 days at controlled and ambient temperature. The results showed that the repackaged ziv-aflibercept remained sterile and stable, with preserved efficacy. However, the concentration of the drug decreased after a certain period of time at specific temperatures.
SCIENTIFIC REPORTS
(2022)
Review
Oncology
Yu-Chien Tsao, Ting-Ying Chen, Li-An Wang, Chia-Chun Lee, Wan-Ju Annabelle Lee, Sheng-Min Hsu, Chi-Chun Lai, Shih-Chieh Shao, Jia-Horung Hung, Edward Chia-Cheng Lai
Summary: This study evaluated the risk of acute kidney injury associated with intravitreal anti-VEGF drugs in patients with retinal diseases through a systematic review and meta-analysis. The results indicated that intravitreal anti-VEGF drugs, including aflibercept and ranibizumab, did not increase the risk of acute kidney injury in patients with various retinal diseases.
Review
Medicine, Research & Experimental
Levon M. Khachigian, Gerald Liew, Kelvin Y. C. Teo, Tien Y. Wong, Paul Mitchell
Summary: Neovascular age-related macular degeneration (nAMD) is a leading cause of visual impairment and blindness, but current anti-VEGF therapies have limitations. This article discusses the need for new and improved therapies for nAMD and explores the efficacy of multi-targeted therapies that target both the VEGF pathway and other pathways.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Medicine, General & Internal
Jae-Hui Kim, Jong-Woo Kim, Chul-Gu Kim
Summary: This study revealed a trend in the selection of ranibizumab and aflibercept for initial treatment of neovascular AMD and PCV, with ranibizumab preferred in older patients and those with type 3 MNV, and aflibercept highly preferred in patients with PCV. The variance in patient characteristics and efficacy of the two agents may have influenced this trend.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Ophthalmology
Charles C. Wykoff, David M. Brown, Kimberly Reed, Alyson J. Berliner, Adam T. Gerstenblith, Aurora Breazna, Prema Abraham, Jordana G. Fein, Karen W. Chu, W. Lloyd Clark, Sergio Leal, Thomas Schmelter, Boaz Hirshberg, George D. Yancopoulos, Robert Vitti, CANDELA Study Investigators
Summary: In patients with neovascular age-related macular degeneration (nAMD), treatment with aflibercept, 8mg, may have greater therapeutic benefits compared with aflibercept, 2mg, including improved outcomes and reduced treatment burden.
JAMA OPHTHALMOLOGY
(2023)
Article
Ophthalmology
Carlos D. Nunez-Amaro, Mariana Lopez, Elva Adan-Castro, Ma. Ludivina Robles-Osorio, Renata Garcia-Franco, Marlon Garcia-Roa, Yolanda Villalpando-Gomez, Paulina Ramirez-Neria, Nayeli Pineiro, Juan Fernando Rubio-Mijangos, Jorge Sanchez, Gabriela Ramirez-Hernandez, Lourdes Siqueiros-Marquez, Nundehui Diaz-Lezama, Ellery Lopez-Star, Thomas Bertsch, Gonzalo Marinez de la Escalera, Jakob Triebel, Carmen Clapp
Summary: Oral levosulpiride for 8 weeks improved visual and structural outcomes in patients with centre-involving diabetic macular oedema (DME) by mechanisms that may include intraocular upregulation of vasoinhibin and downregulation of VEGF and PlGF. Larger clinical trials evaluating long-term efficacy and safety are warranted.
Article
Ophthalmology
Tommes Riemer, Dominique Berndt, Alexander Boeker, Josefine Urban, Ulrike Schrifl, Saskia Rau, Anne Lehmann, Antonia M. Joussen, Oliver Zeitz
Summary: This study analyzes the assumption of interchangeability of bevacizumab, ranibizumab, and aflibercept by assessing the effects of switching from aflibercept or ranibizumab to bevacizumab in real-world conditions. The results show a decrease in visual acuity and an increase in retinal edema after the switch, suggesting that the drugs are not freely interchangeable in this cohort.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
(2023)
Review
Medicine, General & Internal
Andrea C. Tricco, Sonia M. Thomas, Erin Lillie, Areti Angeliki Veroniki, Jemila S. Hamid, Ba' Pham, Taehoon Lee, Arnav Agarwal, Jane P. Sharpe, Alistair Scott, Rachel Warren, Ronak Brahmbhatt, Erin Macdonald, Ghayath Janoudi, Rajeev H. Muni, Carolina L. M. Francisconi, Trevor Richter, Sharon E. Straus
Summary: The study revealed that ranibizumab, bevacizumab, aflibercept, and brolucizumab were statistically superior to conbercept in terms of the proportion of patients with nAMD who experienced moderate vision gain. However, these findings were based on indirect evidence from one small trial and did not account for drug-specific differences.
SYSTEMATIC REVIEWS
(2021)
Article
Ophthalmology
Michael Javaheri, Lauren Hill, Avanti Ghanekar, Ivaylo Stoilov
Summary: In treatment-naive patients with nAMD, approximately one-third achieved flattened PEDs after the initial ranibizumab injection, and approximately one-half after the second injection. However, visual outcomes were not superior among those with PED flattening. Flattening may serve as a marker for less intensive as-needed injection frequencies.
JAMA OPHTHALMOLOGY
(2021)
Article
Ophthalmology
Charles C. Wykoff, David M. Brown, Kimberly Reed, Alyson J. Berliner, Adam T. Gerstenblith, Aurora Breazna, Prema Abraham, Jordana G. Fein, Karen W. Chu, W. Lloyd Clark, Sergio Leal, Thomas Schmelter, Boaz Hirshberg, George D. Yancopoulos, Robert Vitti
Summary: This study evaluated the safety and efficacy of Aflibercept 8mg in patients with nAMD. The results showed that Aflibercept 8mg may have greater therapeutic benefits compared to Aflibercept 2mg in terms of anatomical and visual improvements over a 44-week period, although it did not reach the primary efficacy endpoint at week 16.
JAMA OPHTHALMOLOGY
(2023)
Article
Ophthalmology
Maya H. Maloney, Stephanie R. Payne, Jeph Herrin, Lindsey R. Sangaralingham, Nilay D. Shah, Andrew J. Barkmeier
Summary: This study aimed to compare the systemic safety of intravitreal bevacizumab, ranibizumab, and aflibercept in real-world clinical practice. The results showed no significant differences in the risk of acute myocardial infarction, acute cerebrovascular disease, major bleeding, or all-cause hospitalization after treatment initiation with any of the three anti-VEGF agents.
Review
Ophthalmology
Nadege Ngo Ntjam, Marie Thulliez, Gilles Paintaud, Francesco Salvo, Denis Angoulvant, Pierre-Jean Pisella, Theodora Bejan-Angoulvant
Summary: Intravitreal anti-VEGF therapy did not show an increased risk of major cardiovascular events or total mortality, but may have an increased risk of mortality in patients with diabetic retinopathy and nonocular hemorrhages in patients with AMD. Continued surveillance of systemic adverse events is warranted.
JAMA OPHTHALMOLOGY
(2021)
Article
Medicine, General & Internal
Danyal Malik, Xuan Cao, Jaron Castillo Sanchez, Tianshun Gao, Jiang Qian, Silvia Montaner, Akrit Sodhi
Summary: The study found that patients with ocular vascular diseases may choose a cheaper but non-FDA approved drug, which may be influenced by acts of altruism. Factors such as age, race, sex, presence of diabetes, and type of eye disease were not associated with patients' choice of medication.
